These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35029303)

  • 41. Boosting BNT162b2 vaccine efficacy in CLL.
    Bhat SA; Woyach JA
    Blood; 2022 Feb; 139(5):639-640. PubMed ID: 35113151
    [No Abstract]   [Full Text] [Related]  

  • 42. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Mellinghoff SC; Robrecht S; Mayer L; Weskamm LM; Dahlke C; Gruell H; Vanshylla K; Schlösser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
    Leukemia; 2022 Feb; 36(2):562-565. PubMed ID: 34937858
    [No Abstract]   [Full Text] [Related]  

  • 43. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
    Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
    [No Abstract]   [Full Text] [Related]  

  • 44. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
    Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
    Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
    Belda F; Mora O; Lopez Martinez M; Torres N; Vivanco A; Christie R; Crowley M
    Vaccine; 2022 May; 40(22):2993-2998. PubMed ID: 35443917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
    Friedman-Klabanoff DJ; Tjaden AH; Santacatterina M; Munawar I; Sanders JW; Herrington DM; Wierzba TF; Berry AA;
    Vaccine; 2022 Oct; 40(42):6133-6140. PubMed ID: 36117003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis.
    Ma Y; Liu N; Wang Y; Zeng J; Hu YY; Hao W; Shi H; Zhu P; Lv J; Fan W; Wang X
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34845005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose.
    Rose E; Magliulo D; Kyttaris VC
    Clin Immunol; 2022 Dec; 245():109144. PubMed ID: 36220613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Ujjani C; Greninger AL; Shadman M; Hill JA; Lynch RC; Warren EH; Gopal AK
    Am J Hematol; 2022 Feb; 97(2):E67-E69. PubMed ID: 34807468
    [No Abstract]   [Full Text] [Related]  

  • 51. Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.
    Yin J; Chen Y; Li Y; Zhang X; Wang C
    Hum Vaccin Immunother; 2022 Nov; 18(6):2119763. PubMed ID: 36161976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
    Mehrabi Nejad MM; Shobeiri P; Dehghanbanadaki H; Tabary M; Aryannejad A; Haji Ghadery A; Shabani M; Moosaie F; SeyedAlinaghi S; Rezaei N
    Virol J; 2022 Aug; 19(1):132. PubMed ID: 35941646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. COVID-19 Vaccine Response in People with Multiple Sclerosis.
    Tallantyre EC; Vickaryous N; Anderson V; Asardag AN; Baker D; Bestwick J; Bramhall K; Chance R; Evangelou N; George K; Giovannoni G; Godkin A; Grant L; Harding KE; Hibbert A; Ingram G; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Schmierer K; Scurr MJ; Shah SN; Simmons J; Upcott M; Willis M; Jolles S; Dobson R
    Ann Neurol; 2022 Jan; 91(1):89-100. PubMed ID: 34687063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.
    Lyski ZL; Kim MS; Xthona Lee D; Raué HP; Raghunathan V; Griffin J; Ryan D; Brunton AE; Curlin ME; Slifka MK; Messer WB; Spurgeon SE
    Blood Adv; 2022 Feb; 6(4):1207-1211. PubMed ID: 34872103
    [No Abstract]   [Full Text] [Related]  

  • 56. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.
    Fiorcari S; Atene CG; Maffei R; Debbia G; Potenza L; Luppi M; Marasca R
    Haematologica; 2021 Aug; 106(8):2265-2268. PubMed ID: 33691383
    [No Abstract]   [Full Text] [Related]  

  • 57. Stem cell transplantation in chronic lymphocytic leukaemia - steering a safe course over shifting sands.
    Hallam S; Gribben JG
    Best Pract Res Clin Haematol; 2010 Mar; 23(1):109-19. PubMed ID: 20620975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib.
    Andrick B; Alwhaibi A; DeRemer DL; Quershi S; Khan R; Bryan LJ; Somanath PR; Pantin J
    Br J Haematol; 2018 Sep; 182(5):712-714. PubMed ID: 28737280
    [No Abstract]   [Full Text] [Related]  

  • 59. Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients.
    Patelli G; Pani A; Amatu A; Scaglione F; Sartore-Bianchi A
    Eur J Cancer; 2022 May; 167():175-176. PubMed ID: 35370047
    [No Abstract]   [Full Text] [Related]  

  • 60. Chronic leukaemias: can they be cured? Part II: Chronic lymphocytic leukaemia.
    Mughal TI; Goldman JM
    Br J Clin Pract; 1989 Oct; 43(10):353-6. PubMed ID: 2698240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.